Ticker LaunchReverse merger · Completed · LUMO
Lumos Pharma, Inc.
Reverse merger with NewLink Genetics Corporation (NLNK)
Lumos Pharma, Inc. merged into NewLink Genetics Corporation (NLNK), a Nasdaq-listed biotech with an oncology portfolio, in a reverse merger that takes the private company public. The deal was announced on Sep 30, 2019 and closed on Mar 18, 2020. The combined company trades as Lumos Pharma, Inc. (LUMO) on Nasdaq.
Lumos Pharma is a biopharmaceutical company focused on rare diseases. Its pipeline centers on LUM-201 (ibutamoren), an orally administered small-molecule growth hormone secretagogue for pediatric growth hormone deficiency and other rare endocrine disorders.
- Status
- Completed
- Private company
- Lumos Pharma, Inc.
- Public company
- NewLink Genetics Corporation (NLNK)
- Public company business before
- Nasdaq-listed biotech with an oncology portfolio
- Announced
- Sep 30, 2019
- Closed
- Mar 18, 2020
- Combined company
- Lumos Pharma, Inc. (LUMO)
- Exchange
- Nasdaq
- Sector
- Biotech & pharma
More on this deal for subscribers
- Ownership split between private and public holders
- Reverse stock split
- Analyst notes from the filings
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
Other completed reverse mergers
- Cantek Holdings (2020) Ltd.into Kinetic Group Inc. · Apr 8, 2020
- Worldwide Specialty Chemicals Inc.into Lux Amber, Corp. · Mar 26, 2020
- Duke Robotics, Inc.into UAS Drone Corp. · Mar 10, 2020
- TRICCAR Holdings, Inc.into Frontier Oilfield Services, Inc. · Feb 28, 2020
- Warrender Enterprise Inc. d/b/a Lifted Madeinto Acquired Sales Corp. · Feb 24, 2020
- Jaguaring Company d/b/a Cannavolveinto Intelligent Buying, Inc. · Feb 14, 2020